{"ok":true,"trend":{"id":735372,"platform":"news","region":"global","key":"novartis bets on autoimmune bites through $7.8bn abogen deal","title":"Novartis bets on autoimmune BiTEs through $7.8bn Abogen deal","url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQRExpNDQ3anlJU0ZfYjZHNDRDRHlHX3hyUWV3UHVBRzR6bzYwNmhnZ2xDRU5hWkJsc0VtZkZJUjhCbXJreHNoUEMwS2p6cktRSGhyWXl2WnNFbnYxVE16TTFDQVZ3R2ZybzZENmZQMnBrSW1JWklmTXdSaXFVcXEwcGJpWkxseFRRSzZlb2pVWDE0ckFvYnB6Sl9SQzNiajJn?oc=5","first_seen":"2026-10-02T12:51:13.965648Z","last_seen":"2026-10-02T12:51:13.965648Z","last_rank":31,"peak_rank":31,"last_volume":null,"peak_volume":null,"seen_count":1,"score":0.671875,"category_hint":"technology","section":"technology","category":"technology","summary":"Novartis has agreed to acquire Chinese biotech Abogen in a deal worth $7.8bn, betting on bispecific T-cell engagers (BiTEs) aimed at autoimmune diseases. The move signals the Swiss drugmaker's push into next-generation immunology therapies, expanding its pipeline beyond traditional treatments. Industry watchers see it as part of a broader wave of big pharma deals targeting autoimmune conditions with engineered antibody technologies.","why":"The $7.8bn acquisition is a major pharma deal that could reshape Novartis's autoimmune drug pipeline.","tone":"neutral","entities":["Novartis","Abogen"],"summarized_at":"2026-10-02T12:52:20.572916Z","meta":{"via":"scan","lang":"en","term":"technology","source":"Pharmaceutical Technology","published":"Fri, 02 Oct 2026 11:18:52 GMT"},"nw":null,"promo":null,"kind":null,"importance":null,"hidden":false,"hide_reason":null,"judged_at":null,"title_en":"Novartis to buy Abogen for $7.8bn in autoimmune BiTE push","section_name":"Technology","category_name":"Technology","timeline":[{"captured_at":"2026-10-02T12:51:13.965648Z","rank":31,"volume":null}],"posts":[{"platform":"news","url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQRExpNDQ3anlJU0ZfYjZHNDRDRHlHX3hyUWV3UHVBRzR6bzYwNmhnZ2xDRU5hWkJsc0VtZkZJUjhCbXJreHNoUEMwS2p6cktRSGhyWXl2WnNFbnYxVE16TTFDQVZ3R2ZybzZENmZQMnBrSW1JWklmTXdSaXFVcXEwcGJpWkxseFRRSzZlb2pVWDE0ckFvYnB6Sl9SQzNiajJn?oc=5","author":"Pharmaceutical Technology","title":"Novartis bets on autoimmune BiTEs through $7.8bn Abogen deal","snippet":null,"posted_at":"2026-10-02T11:18:52Z","likes":null}],"elsewhere":[],"window":"7d"}}